NASDAQ:SLN Silence Therapeutics Q3 2026 Earnings Results & Report $19.77 +0.01 (+0.03%) As of 10:08 AM Eastern This is a fair market value price provided by Massive. Learn more. Silence Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.24 versus the -$0.1129 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market OpensConference Call2:00 AM ET Silence Therapeutics EPS ResultsActual EPS-$0.24Consensus EPS -$0.1129Beat/MissMissed by -$0.1271One Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersSilence Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$113 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Silence Therapeutics Q3 2026 Earnings FAQ Did Silence Therapeutics beat earnings estimates for Q3 2026? Silence Therapeutics (NASDAQ:SLN) reported earnings of -$0.24 per share for Q3 2026, missing the consensus estimate of -$0.1129. The report was announced on Thursday, November 12, 2026. Silence Therapeutics Earnings HeadlinesSilence Therapeutics plc: Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results54 minutes ago | finanznachrichten.deSilence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLNOctober 21, 2026 | businesswire.comWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of AI." Musk's track record includes PayPal, Tesla and SpaceX. Tim Bohen has put the details of what he calls Musk's Mission X into a brand-new masterclass, free to watch with no credit card required. Viewers also receive a free ticker tied to Mission X.November 12 at 1:00 AM | StocksToTrade (Ad)BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)October 20, 2026 | globenewswire.comSilence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%October 19, 2026 | insidermonkey.comSilence Therapeutics to Be Acquired by Germany's Merck in $1.3 Billion Deal; Shares SurgeOctober 19, 2026 | finance.yahoo.comSee More Silence Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silence Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silence Therapeutics and other key companies, straight to your email. Email Address About Silence TherapeuticsSilence Therapeutics (NASDAQ:SLN) is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders. Silence Therapeutics focuses on developing medicines rather than selling marketed products, and it has worked with pharmaceutical partners to advance RNAi programs. Founded in 1994, the company has roots in Germany and is headquartered in London. Its activities include research, drug development and collaborations with partners in markets beyond the United Kingdom.View Silence Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going Away Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
